Advanced Proteome Therapeutics Corp. (NYSE:APC) has earned an average recommendation of “Buy” from the thirty analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is C$66.14.

Several equities analysts have weighed in on the company. Stifel Nicolaus dropped their target price on Advanced Proteome Therapeutics Corp. from $73.00 to $72.00 and set a “buy” rating for the company in a research report on Wednesday, November 1st. Scotiabank reaffirmed a “buy” rating and issued a $62.00 target price on shares of Advanced Proteome Therapeutics Corp. in a research report on Wednesday, November 1st. Atlantic Securities raised Advanced Proteome Therapeutics Corp. from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $49.05 to $62.00 in a research report on Friday, October 6th. Morgan Stanley set a $55.00 price objective on Advanced Proteome Therapeutics Corp. and gave the company a “hold” rating in a research note on Wednesday, October 18th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $57.00 price objective on shares of Advanced Proteome Therapeutics Corp. in a research note on Tuesday, October 10th.

ILLEGAL ACTIVITY WARNING: “Advanced Proteome Therapeutics Corp. (APC) Receives C$66.14 Consensus Price Target from Analysts” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/advanced-proteome-therapeutics-corp-apc-receives-c66-14-consensus-price-target-from-analysts/1697148.html.

Several large investors have recently added to or reduced their stakes in APC. Fis Group Inc. acquired a new position in shares of Advanced Proteome Therapeutics Corp. in the third quarter valued at approximately $107,000. Stelac Advisory Services LLC acquired a new position in shares of Advanced Proteome Therapeutics Corp. in the third quarter valued at approximately $107,000. FNY Partners Fund LP increased its holdings in shares of Advanced Proteome Therapeutics Corp. by 2,900.0% in the second quarter. FNY Partners Fund LP now owns 3,000 shares of the energy producer’s stock valued at $136,000 after purchasing an additional 2,900 shares during the period. Sun Life Financial INC increased its holdings in shares of Advanced Proteome Therapeutics Corp. by 1,363.4% in the second quarter. Sun Life Financial INC now owns 3,000 shares of the energy producer’s stock valued at $136,000 after purchasing an additional 2,795 shares during the period. Finally, YorkBridge Wealth Partners LLC increased its holdings in shares of Advanced Proteome Therapeutics Corp. by 12.5% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,606 shares of the energy producer’s stock valued at $166,000 after purchasing an additional 402 shares during the period.

Advanced Proteome Therapeutics Corp. (APC) opened at C$51.11 on Friday. Advanced Proteome Therapeutics Corp. has a 52-week low of C$39.96 and a 52-week high of C$73.33.

Advanced Proteome Therapeutics Corp. (NYSE:APC) last released its earnings results on Tuesday, October 31st. The energy producer reported C($0.77) earnings per share for the quarter, missing the consensus estimate of C($0.56) by C($0.21). The firm had revenue of C$2.50 billion during the quarter, compared to analyst estimates of C$2.52 billion. Advanced Proteome Therapeutics Corp. had a negative net margin of 24.56% and a negative return on equity of 25.27%. The business’s revenue was up 31.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.89) earnings per share.

Advanced Proteome Therapeutics Corp. declared that its board has initiated a share buyback plan on Wednesday, September 20th that authorizes the company to repurchase $2.50 billion in outstanding shares. This repurchase authorization authorizes the energy producer to reacquire up to 10% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

About Advanced Proteome Therapeutics Corp.

Anadarko Petroleum Corporation (Anadarko) is an independent exploration and production company. The Company is engaged in developing, acquiring, and exploring for oil and natural-gas resources. The Company’s segments include Oil and Gas Exploration and Production; Midstream, and Marketing. The Company’s geographical segments include the United States and International.

Analyst Recommendations for Advanced Proteome Therapeutics Corp. (NYSE:APC)

Receive News & Ratings for Advanced Proteome Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Proteome Therapeutics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.